JP2024105460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105460A5 JP2024105460A5 JP2024076310A JP2024076310A JP2024105460A5 JP 2024105460 A5 JP2024105460 A5 JP 2024105460A5 JP 2024076310 A JP2024076310 A JP 2024076310A JP 2024076310 A JP2024076310 A JP 2024076310A JP 2024105460 A5 JP2024105460 A5 JP 2024105460A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- diffraction pattern
- pharmaceutical composition
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 238000002441 X-ray diffraction Methods 0.000 claims 6
- 230000005855 radiation Effects 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims 3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692914P | 2018-07-02 | 2018-07-02 | |
| US62/692,914 | 2018-07-02 | ||
| JP2020572517A JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態 |
| PCT/US2019/040276 WO2020010068A1 (en) | 2018-07-02 | 2019-07-02 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Division JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078385A Division JP2026129937A (ja) | 2018-07-02 | 2026-05-07 | 2-(3,5-ジクロロ-4-((5-イソプロピル-6-オキソ-1,6-ジヒドロピリダジン-3-イル)オキシ)フェニル)-3,5-ジオキソ-2,3,4,5-テトラヒドロ-1,2,4-トリアジン-6-カルボニトリルの固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105460A JP2024105460A (ja) | 2024-08-06 |
| JP2024105460A5 true JP2024105460A5 (cg-RX-API-DMAC10.html) | 2025-02-07 |
Family
ID=67441642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Pending JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態 |
| JP2024076310A Pending JP2024105460A (ja) | 2018-07-02 | 2024-05-09 | 2-(3,5-ジクロロ-4-((5-イソプロピル-6-オキソ-1,6-ジヒドロピリダジン-3-イル)オキシ)フェニル)-3,5-ジオキソ-2,3,4,5-テトラヒドロ-1,2,4-トリアジン-6-カルボニトリルの固体形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Pending JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態 |
Country Status (12)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| CN119431265A (zh) | 2019-02-21 | 2025-02-14 | 南京瑞捷医药科技有限公司 | 一种作为甲状腺激素受体激动剂的化合物 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| KR20230066408A (ko) | 2020-09-10 | 2023-05-15 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도 |
| US12616701B2 (en) | 2020-10-19 | 2026-05-05 | Assia Chemical Industries Ltd | Solid state forms of Resmetirom |
| WO2022165227A1 (en) * | 2021-02-01 | 2022-08-04 | Madrigal Pharmaceuticals, Inc. | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| US20240218009A1 (en) * | 2021-04-21 | 2024-07-04 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| TW202337470A (zh) | 2021-09-27 | 2023-10-01 | 美商瑪德瑞高製藥公司 | 用於縮減肝臟體積之瑞美替隆 |
| MX2024005647A (es) * | 2021-11-11 | 2024-05-24 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. |
| JP2026521649A (ja) | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | THR-βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| EP4762048A2 (en) | 2023-10-16 | 2026-06-24 | Cipla Limited | Resmetirom polymorphs and process for their preparation |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025172958A1 (en) * | 2024-02-16 | 2025-08-21 | Metrochem Api Pvt Ltd | Solid state forms of resmetirom |
| WO2025231587A1 (zh) * | 2024-05-06 | 2025-11-13 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗无水晶型ch及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
| WO2026107045A1 (en) | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| ATE480524T1 (de) * | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| ES2795450T3 (es) * | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) * | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| US12616701B2 (en) * | 2020-10-19 | 2026-05-05 | Assia Chemical Industries Ltd | Solid state forms of Resmetirom |
-
2019
- 2019-07-01 TW TW114125593A patent/TW202615431A/zh unknown
- 2019-07-01 TW TW108123112A patent/TW202019914A/zh unknown
- 2019-07-01 AR ARP190101846A patent/AR115666A1/es unknown
- 2019-07-02 MX MX2021000107A patent/MX2021000107A/es unknown
- 2019-07-02 EP EP19745399.6A patent/EP3818057A1/en not_active Withdrawn
- 2019-07-02 IL IL321116A patent/IL321116A/en unknown
- 2019-07-02 US US17/257,070 patent/US20210122740A1/en not_active Abandoned
- 2019-07-02 KR KR1020257038532A patent/KR20250167140A/ko not_active Ceased
- 2019-07-02 WO PCT/US2019/040276 patent/WO2020010068A1/en not_active Ceased
- 2019-07-02 KR KR1020217003360A patent/KR102890565B1/ko active Active
- 2019-07-02 JP JP2020572517A patent/JP2021530456A/ja active Pending
- 2019-07-02 EP EP24214548.0A patent/EP4552643A3/en active Pending
- 2019-07-02 CA CA3104860A patent/CA3104860A1/en active Pending
- 2019-07-02 AU AU2019298236A patent/AU2019298236A1/en not_active Abandoned
- 2019-07-02 CN CN201980056826.0A patent/CN112638904A/zh active Pending
-
2020
- 2020-12-23 IL IL279700A patent/IL279700A/en unknown
-
2021
- 2021-01-06 MX MX2023009701A patent/MX2023009701A/es unknown
- 2021-01-06 MX MX2024013198A patent/MX2024013198A/es unknown
-
2024
- 2024-05-09 JP JP2024076310A patent/JP2024105460A/ja active Pending
- 2024-11-15 US US18/949,309 patent/US20250074898A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200189A patent/AU2025200189A1/en active Pending
- 2025-08-19 US US19/303,585 patent/US20250368626A1/en active Pending